An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Rintatolimod (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Adverse reactions; Registrational
- Sponsors Hemispherx Biopharma
- 21 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 21 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 22 Apr 2016 Study design changed from parallel to single group and treatment arms changed from 3 to 1.